Medical/Pharmaceuticals
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...
2023-12-11 20:00
1356
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...
2023-12-11 20:00
1581
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
2023-12-11 19:40
1528
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering - 70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors - Demonstrated a confirmed objecti...
2023-12-11 18:55
1420
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Offi...
2023-12-11 18:00
1667
Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib
SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study ...
2023-12-11 13:30
1403
Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%
SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety...
2023-12-11 13:14
1429
MGI Expands Presence in Latin America with New Partnerships with Genos Médica and TCL Group
SAO PAULO, Dec. 10, 2023 /PRNewswire/ -- MGI Tech Co. Ltd., a company committed to building core tools and technology to lead life science, today announced partnerships with Genos Médica, aMexico-based specialized center in genomics, and TCL Group, a company dedicated to the import and sales of l...
2023-12-11 11:26
1562
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
CAMBRIDGE, Mass., Dec. 10, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and Evive Biotech, a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwid...
2023-12-11 09:00
1476
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will evaluate the safety and preliminary efficacy of ATG-031 in patients withadvanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). * ATG-031, discovered and developed in-house by Antengene, is t...
2023-12-11 08:30
1679
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published inThe Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Ex...
2023-12-10 18:00
1820
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
* This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. * This analysis shows a clinically meaningful improvement in progression-free survivala...
2023-12-08 23:13
3722
Whole Exome Sequencing Advancements in Unraveling Rare Diseases in Japan
TOKYO, Dec. 8, 2023 /PRNewswire/ -- According to Estimation of the Number of
Patients With Mitochondrial Diseases: A Descriptive Study Using in a nationwide
database inJapan
2023-12-08 13:40
1912
PharmaBlock Officially Joins United Nations Global Compact
NANJING, China, Dec. 8, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has officially joined the United Nations Global Compact (UNGC), which not only affi...
2023-12-08 12:37
1607
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. * This marks the 13th NDA approval obtained by CSt...
2023-12-08 12:10
5620
CU Medicine study published in The Lancet Infectious Diseases concludes that a novel oral microencapsulated live bacteria consortia (SIM01) alleviates long COVID symptoms
HONG KONG, Dec. 8, 2023 /PRNewswire/ -- A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by TheChinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula (SIM01)...
2023-12-08 10:38
2332
Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals
GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux,Belgium, for radiopharmaceuticals. ...
2023-12-08 10:00
1605
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. * Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and ...
2023-12-08 07:39
1943
2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer
NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 202...
2023-12-07 21:00
1423
Unlocking the Potential of Multi-Omics in Precision Medicine: A Conversation with Kazusa DNA Research Institute
CHIBA, Japan, Dec. 7, 2023 /PRNewswire/ -- The integration of multi-omics approaches offers a comprehensive panorama for advancing our comprehension of biology. It now plays a more important role in understanding the roots of diseases, and in expediting precision medicine and catalyzing advanceme...
2023-12-07 15:37
1920
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 307 media titles]
2025-01-06 14:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 292 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
11036
JS Group Celebrates a Decade of Excellence at 10th Anniversary Gala Highlights Milestones, Partnerships, and a Vision for the Future
2025-01-03 17:51
5636
